Subscribe To
IQV / IQVIA: A Clear Case Of Why High ROIC Justifies High P/E Rating
IQV News
By Zacks Investment Research
November 1, 2023
IQVIA Holdings (IQV) Q3 Earnings Surpass Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to ea more_horizontal
By Zacks Investment Research
October 5, 2023
IQVIA (IQV) and argenx Partner to Advance Autoimmune Care
IQVIA (IQV) and argenx expand collaboration to advance rare autoimmune treatments through innovative pharmacovigilance. more_horizontal
By Market Watch
October 2, 2023
Court strikes down federal rule that sharply increased prescription costs for many patients
A federal court on Friday struck down a rule that sharply increased out-of-pocket prescription costs for many patients with complex conditions. more_horizontal
By Zacks Investment Research
September 8, 2023
Here's Why Investors Should Retain IQVIA (IQV) Stock Now
An addressable market size and strong healthcare-specific global IT infrastructure boost IQVIA (IQV). more_horizontal
By InvestorPlace
August 30, 2023
3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of
This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so more_horizontal
By Zacks Investment Research
August 25, 2023
IQVIA (IQV) Stock Improves 8% in Three Months: Here's How
IQVIA (IQV) aims at market expansion through innovation and service improvements. more_horizontal
By Zacks Investment Research
August 1, 2023
IQVIA Holdings' (IQV) Q2 Earnings Beat Estimates, Decline Y/Y
IQVIA Holdings (IQV) second-quarter 2023 revenues improve year over year. more_horizontal
By Zacks Investment Research
August 1, 2023
IQVIA (IQV) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering more_horizontal